Wound Healing Clinical Trial
Official title:
A Phase II, Closed Label, Randomized, Double Blind Study for the Treatment of Acute Induced Wounds With TolaSure Gel, 5% w/w in Healthy Volunteers
Verified date | June 2020 |
Source | BioMendics, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
TolaSure is a topical gel for the promotion of accelerated wound healing. This phase II study will primarily assess the efficacy of TolaSure when applied to skin wounds created by punch biopsy in healthy participants. Safety, cutaneous tolerability, wound pain control, and quality of healing will also be assessed. A total of 80 healthy volunteers, males and females ages 18 years or older, will be enrolled. Subjects will be monitored for safety and efficacy until wound closure (estimation about 8 weeks) following topical administration of TolaSure.
Status | Completed |
Enrollment | 72 |
Est. completion date | April 22, 2020 |
Est. primary completion date | April 22, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Healthy Males and Females > 18 years of age - Health history review - Physical exam - Blood and urine clinical chemistries - Negative pregnancy test Exclusion Criteria: - Acute or chronic skin disorders (e.g. psoriasis); - Acne or dermatitis at the test site; - Prone to keloids or hypertrophic scarring; - Topical or systemic antibiotics within 4 weeks of study enrollment; - Subjects with known severe mental illness which, in the investigator's opinion, may prevent informed consent or interfere with the subject's ability to comply with study protocol procedures; - Diagnosed with Diabetes Type I/II or glucose results indicative of prediabetic condition; - Morbidly obese with a Body Mass Index (BMI) = 40; - Surgery within the previous 3 months (except for minor cosmetic or dental procedures) - History of severe vitamin or mineral deficiency; - History of drug or alcohol abuse (as defined by the Investigator); - Smoking/Vaping; - HIV/AIDS; - Consistently taking steroids and/or non-steroidal anti-inflammatory drugs. Subjects may use NSAIDs on an as needed basis with no more than 7 days of consecutive use; - Cancer diagnosis in the last 5 years; - Currently receiving chemotherapy or radiation; - Women who are pregnant, nursing, or planning a pregnancy; - Hyper- or hypo-pigmentation, or tattoos in the area where they will place the test fields; - Symptoms of a clinically significant illness in the four weeks before treatment application that may influence the outcome of the study; - Treatment with any investigational agent within one month before treatment application for this trial; - Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule; - Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment. |
Country | Name | City | State |
---|---|---|---|
United States | J&S Studies | College Station | Texas |
United States | University of Miami | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
BioMendics, LLC | Symbio, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Accelerated Wound Closure | Time-to-closure will be calculated by the number of days from biopsy to wound closure. Wound closure (changes in wound area (mm^2) over time) will be determined by the digital imaging platform software with Principal Investigator confirmation. | Day 1, 2, and 7, then weekly until closure (estimated 8 weeks) | |
Secondary | Percent Area Reduction after Four Weeks | Wound area measurements (mm^2) will be calculated at week 4 by using a digital imaging. A percent reduction in area at week 4 will be calculated by comparing the initial area of the biopsy at Day 1 to the week 4 biopsy area. | Week 4 | |
Secondary | Wound Pain Control | Wound-related pain or discomfort will be assessed, using the Visual Analog Scale (VAS) for Pain, for each individual wound site as pain at rest followed by pain to touch.
The VAS Pain is a continuous scale comprised of a horizontal line, 10 centimeters (100 mm) in length. Pain will be defined per the following scale: None - 0-4 mm; Mild - 5-44 mm: Moderate - 45-74; Severe - 75-100 mm |
Day 2 and 7, then weekly until wound closure (estimated 8 weeks) | |
Secondary | Quality of Healing | Patient and Observer Scar Assessment Scale (POSAS) version 2.0 will be used to assess the quality of healing of each biopsy site at the end of the study once both wounds are closed. | End of study (estimated 8 weeks) | |
Secondary | Cutaneous Tolerability | Cutaneous tolerability will include an evaluation of erythema and edema following the modified Draize scoring system. Draize scores will be recorded and changes from baseline Draize scores will be monitored over the course of the time frame.
Draize Scoring System. Erythema: 0-No Erythema, 1-Slight Erythema, 2-Well Defined Erythema, 3- Moderate or Severe Erythema, 4- Severe Erythema or slight eschar formation. Edema: 0- No Edema, 1- Very Slight Edema(barely perceptible), 2-Slight Edema (well defined edges), 3-Moderate Edema (raised >1mm), 4- Severe Edema (raised >1mm and extending beyond the area of exposure) |
Day 1, 2, and 7, then weekly until wound closure (estimated 8 weeks) | |
Secondary | Blood and Urine Chemistries | Absolute values and changes over time of clinical chemistries including; Absolute values and changes over time of clinical blood and urine chemistries including; Hematology and Coagulation, Coagulation, Serum Chemistry, and Urinalysis. Blood and urine analytes are measured on a per mL basis. | Screening, Day 2 and 7, then weekly until wound closure (estimated 8 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05045183 -
A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated
|
N/A | |
Enrolling by invitation |
NCT04613336 -
Efficacy of Topical Heparin Spray on Donor Site Wound Healing Time Compared to Conventional Dressing Among Patients Undergoing Split Thickness Skin Grafting
|
||
Recruiting |
NCT02241811 -
Wound Treatment With 3% Sodium Pentaborate Pentahydrate
|
Phase 1 | |
Completed |
NCT02797899 -
Effect of PRF Palatal Bandage on Pain Scores and Wound Healing After Free Gingival Graft
|
N/A | |
Completed |
NCT01227759 -
Tyrosur® Gel-Investigation on Wound Healing Efficacy
|
Phase 2 | |
Completed |
NCT01061502 -
Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds
|
Phase 1/Phase 2 | |
Completed |
NCT00736593 -
A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.
|
Phase 1 | |
Completed |
NCT00977951 -
Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03872544 -
Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Enrolling by invitation |
NCT03880188 -
Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Recruiting |
NCT05191082 -
Manufacturing, Characterization and Evaluation of the Effect of Silk Fibroin Membranes, Loaded or Not With Neurotensins on Open Wounds in the Palate
|
N/A | |
Enrolling by invitation |
NCT05942235 -
The Use of Microlearning in Nursing Education
|
||
Completed |
NCT03433820 -
Wound Healing in Healthy Volunteers
|
N/A | |
Withdrawn |
NCT02383992 -
Postoperative Care of Sutured Wounds
|
N/A | |
Recruiting |
NCT02034539 -
VADOplex Critical Limb Ischemia Study
|
Phase 2/Phase 3 | |
Recruiting |
NCT01680042 -
Clinical Effect of Phenytoin Mucoadhesive Paste on Wound Healing After Oral Biopsy
|
Phase 1 | |
Completed |
NCT01734317 -
An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.
|
N/A | |
Withdrawn |
NCT01008111 -
Wound Healing of Incisional Wounds for Bilateral Hernia Repair
|
Phase 1 | |
Completed |
NCT01115218 -
The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy
|
||
Completed |
NCT00984503 -
Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites
|
Phase 2 |